These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 33379361)

  • 1. Specific Targeting of PEGylated Liposomal Doxorubicin (Doxil
    Aldughaim MS; Muthana M; Alsaffar F; Barker MD
    Molecules; 2020 Dec; 26(1):. PubMed ID: 33379361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liposomal formulation of Galbanic acid improved therapeutic efficacy of pegylated liposomal Doxorubicin in mouse colon carcinoma.
    Nik ME; Malaekeh-Nikouei B; Amin M; Hatamipour M; Teymouri M; Sadeghnia HR; Iranshahi M; Jaafari MR
    Sci Rep; 2019 Jul; 9(1):9527. PubMed ID: 31267009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin.
    Arabi L; Badiee A; Mosaffa F; Jaafari MR
    J Control Release; 2015 Dec; 220(Pt A):275-286. PubMed ID: 26518722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model.
    Moosavian SA; Abnous K; Badiee A; Jaafari MR
    Colloids Surf B Biointerfaces; 2016 Mar; 139():228-36. PubMed ID: 26722819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving anti-tumour efficacy of PEGylated liposomal doxorubicin by dual targeting of tumour cells and tumour endothelial cells using anti-p32 CGKRK peptide.
    Mashreghi M; Faal Maleki M; Karimi M; Kalalinia F; Badiee A; Jaafari MR
    J Drug Target; 2021 Jul; 29(6):617-630. PubMed ID: 33393376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced tumor delivery and antitumor activity in vivo of liposomal doxorubicin modified with MCF-7-specific phage fusion protein.
    Wang T; Hartner WC; Gillespie JW; Praveen KP; Yang S; Mei LA; Petrenko VA; Torchilin VP
    Nanomedicine; 2014 Feb; 10(2):421-30. PubMed ID: 24028893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coupling of a Novel TIMP3 Peptide to Carboxypeptidase G2 for Pro-Drug Activation at the Tumour Site.
    Aldughaim MS; Alsaffar F; Barker MD
    Molecules; 2021 Jan; 26(3):. PubMed ID: 33504102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies.
    Gabizon A; Shmeeda H; Barenholz Y
    Clin Pharmacokinet; 2003; 42(5):419-36. PubMed ID: 12739982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer.
    Charrois GJ; Allen TM
    Biochim Biophys Acta; 2004 May; 1663(1-2):167-77. PubMed ID: 15157619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study of FA12 peptide-modified PEGylated liposomal doxorubicin (PLD) as an effective ligand to target Muc1 in mice bearing C26 colon carcinoma: in silico, in vitro, and in vivo study.
    Biabangard A; Asoodeh A; Jaafari MR; Mashreghi M
    Expert Opin Drug Deliv; 2022 Dec; 19(12):1710-1724. PubMed ID: 36373415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
    Mamidi RN; Weng S; Stellar S; Wang C; Yu N; Huang T; Tonelli AP; Kelley MF; Angiuoli A; Fung MC
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1173-84. PubMed ID: 20661737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models.
    Gabizon A; Tzemach D; Mak L; Bronstein M; Horowitz AT
    J Drug Target; 2002 Nov; 10(7):539-48. PubMed ID: 12683721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiolabeled liposome imaging determines an indication for liposomal anticancer agent in ovarian cancer mouse xenograft models.
    Ito K; Hamamichi S; Asano M; Hori Y; Matsui J; Iwata M; Funahashi Y; Umeda IO; Fujii H
    Cancer Sci; 2016 Jan; 107(1):60-7. PubMed ID: 26509883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A simple way to enhance Doxil® therapy: drug release from liposomes at the tumor site by amphiphilic block copolymer.
    Zhao Y; Alakhova DY; Kim JO; Bronich TK; Kabanov AV
    J Control Release; 2013 May; 168(1):61-9. PubMed ID: 23474033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the leptin receptor: To evaluate therapeutic efficacy and anti-tumor effects of Doxil, in vitro and in vivo in mice bearing C26 colon carcinoma tumor.
    Amiri Darban S; Nikoofal-Sahlabadi S; Amiri N; Kiamanesh N; Mehrabian A; Zendehbad B; Gholizadeh Z; Jaafari MR
    Colloids Surf B Biointerfaces; 2018 Apr; 164():107-115. PubMed ID: 29413587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmaceutical and biomedical differences between micellar doxorubicin (NK911) and liposomal doxorubicin (Doxil).
    Tsukioka Y; Matsumura Y; Hamaguchi T; Koike H; Moriyasu F; Kakizoe T
    Jpn J Cancer Res; 2002 Oct; 93(10):1145-53. PubMed ID: 12417045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-tumor effect via passive anti-angiogenesis of PEGylated liposomes encapsulating doxorubicin in drug resistant tumors.
    Kibria G; Hatakeyama H; Sato Y; Harashima H
    Int J Pharm; 2016 Jul; 509(1-2):178-187. PubMed ID: 27234700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines.
    Elbayoumi TA; Torchilin VP
    Eur J Pharm Sci; 2007 Nov; 32(3):159-68. PubMed ID: 17707615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model.
    Zahmatkeshan M; Gheybi F; Rezayat SM; Jaafari MR
    Eur J Pharm Sci; 2016 Apr; 86():125-35. PubMed ID: 26972276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effective suppression of tumour cells by oligoclonal HER2-targeted delivery of liposomal doxorubicin.
    Farasat A; Rahbarizadeh F; Ahmadvand D; Ranjbar S; Khoshtinat Nikkhoi S
    J Liposome Res; 2019 Mar; 29(1):53-65. PubMed ID: 29621912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.